Literature DB >> 7326200

Oestrogen and progesterone cytosolic receptors in clinically inflammatory tumours of the human breast.

J C Delarue, F May-Levin, H Mouriesse, G Contesso, H Sancho-Garnier.   

Abstract

Oestrogen (RE) and progesterone (RP) cytosolic receptors have been studied in 59 clinically inflammatory tumours of the human breast. The results were compared to those obtained in a series of 496 operable tumours. A single saturating dose of oestradiol for RE and R 5020 for RP was used and the cut-off between negative and positive tumours was 100 fmol/g tissue. A significant difference was seen (P less than 0.02) between the 2 classes of patients: (RE-, RP-) tumours were commoner among clinically inflammatory tumours (48%) than among operable ones (28%), independently of menopause. Concerning the histological type (based on an assessment of differentiation) and the histological grading (Scarff and Bloom) there was a significant difference (P less than 0.001) between the 2 populations of tumours. No significant difference was found in the distribution of RE and RP among the 3 histological types, whereas a significant correlation existed between histological grading and RE (P less than 0.02). Finally, patients with RE+ clinically inflammatory tumours constitute a lower risk group, especially when they are free of metastases at the time of diagnosis. The presence of RE therefore seems to indicate, as in the operable tumour group, a favourable prognosis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7326200      PMCID: PMC2010858          DOI: 10.1038/bjc.1981.291

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  25 in total

1.  Predicting response to endocrine therapy in human breast cancer: a hypothesis.

Authors:  K B Horwitz; W L McGuire
Journal:  Science       Date:  1975-08-29       Impact factor: 47.728

2.  The lack of relationship between estrogen receptor status and response to chemotherapy.

Authors:  R Hilf; M L Feldstein; E D Savlov; S L Gibson; B Seneca
Journal:  Cancer       Date:  1980-12-15       Impact factor: 6.860

3.  [Human mammary carcinoma: relationship between steroid hormone receptors and histopathology. An hypothesis, the prognostic value of hormone receptors (author's transl)].

Authors:  P M Martin; J Jacquemier; P H Rolland; A M Rolland; M Toga
Journal:  Bull Cancer       Date:  1978       Impact factor: 1.276

4.  The prognostic value of estrogen receptor determinations in patients with primary breast cancer: an update.

Authors:  P Furmanski; D E Saunders; S C Brooks; M A Rich
Journal:  Cancer       Date:  1980-12-15       Impact factor: 6.860

5.  Analysis of estradiol and progesterone receptors in early and advanced breast tumors.

Authors:  R J King
Journal:  Cancer       Date:  1980-12-15       Impact factor: 6.860

6.  Correlation of hormone receptors with pathological features in human breast cancer.

Authors:  R R Millis
Journal:  Cancer       Date:  1980-12-15       Impact factor: 6.860

7.  Correlation of estrogen and progesterone receptors with histologic differentiation in mammary carcinoma.

Authors:  K S McCarty; T K Barton; B F Fetter; B H Woodard; J A Mossler; W Reeves; J Daly; W E Wilkinson; K S McCarty
Journal:  Cancer       Date:  1980-12-15       Impact factor: 6.860

8.  [The anatomopathological factors of prognostic value in breast cancer].

Authors:  G Contesso; J Rouéssé; J Y Petit; H Mouriesse
Journal:  Bull Cancer       Date:  1977       Impact factor: 1.276

9.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1976-12       Impact factor: 7.640

10.  Relationship between oestrogen-receptor content and histological grade in human primary breast tumours.

Authors:  P V Maynard; C J Davies; R W Blamey; C W Elston; J Johnson; K Griffiths
Journal:  Br J Cancer       Date:  1978-12       Impact factor: 7.640

View more
  8 in total

1.  Inflammatory carcinoma of the breast: results of a combined-modality approach--M.D. Anderson Cancer Center experience.

Authors:  E H Koh; A U Buzdar; F C Ames; S E Singletary; M D McNeese; D Frye; F A Holmes; G Fraschini; V Hug; R L Theriault
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 2.  Management of inflammatory breast cancer.

Authors:  S E Singletary; F C Ames; A U Buzdar
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

3.  Human monocytes augment invasiveness and proteolytic activity of inflammatory breast cancer.

Authors:  Mona Mostafa Mohamed; Dora Cavallo-Medved; Bonnie F Sloane
Journal:  Biol Chem       Date:  2008-08       Impact factor: 3.915

Review 4.  Progesterone receptors and human breast cancer.

Authors:  G M Clark; W L McGuire
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

5.  Lapatinib inhibits doxorubicin induced migration of HER2-positive breast cancer cells.

Authors:  Naveen Chintalaramulu; Raja Vadivelu; Nam-Trung Nguyen; Ian Edwin Cock
Journal:  Inflammopharmacology       Date:  2020-05-06       Impact factor: 4.473

Review 6.  Inflammatory breast cancer: New factors contribute to disease etiology: A review.

Authors:  Mona M Mohamed; Diaa Al-Raawi; Salwa F Sabet; Mohamed El-Shinawi
Journal:  J Adv Res       Date:  2013-06-14       Impact factor: 10.479

7.  NF-kappa B genes have a major role in inflammatory breast cancer.

Authors:  Florence Lerebours; Sophie Vacher; Catherine Andrieu; Marc Espie; Michel Marty; Rosette Lidereau; Ivan Bieche
Journal:  BMC Cancer       Date:  2008-02-04       Impact factor: 4.430

Review 8.  Update on inflammatory breast cancer.

Authors:  Florence Lerebours; Ivan Bieche; Rosette Lidereau
Journal:  Breast Cancer Res       Date:  2005-01-20       Impact factor: 6.466

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.